
Currently out of the existing stock ratings of Matt Hewitt, 174 are a BUY (85.71%), 29 are a HOLD (14.29%).
Analyst Matt Hewitt, currently employed at CRAIG HALLUM, has had 49.09% of price targets met with an average potential upside of 52.15%, reached in 361 days on average.
Matt Hewitt has documented 398 price targets and ratings displayed on 38 stocks. The coverage is on Healthcare, Technology, Consumer Cyclical, Industrials sectors.
Most recent stock forecast was given on HSTM, HealthStream at 03-Nov-2026.
Analyst best performing recommendations are on CSBR (CHAMPIONS ONCOLOGY).
The best stock recommendation documented was for CSBR (CHAMPIONS ONCOLOGY) on 12/12/2024. The price target of $8 was fulfilled within 11 days with a profit of $2.84 (55.04%), with a performance score of 50.04.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 16-Mar-2021
$12
$12
2 years 10 days ago
(07-Nov-2024)
10/13 (76.92%)
$-0.24 (-1.96%)
27
Buy Since 09-Nov-2020
$14
$14
2 years 1 months 18 days ago
(30-Sep-2024)
5/9 (55.56%)
$2.62 (23.02%)
59
Buy Since 16-Oct-2019
$12
$12
2 years 2 months 7 days ago
(10-Sep-2024)
4/8 (50%)
$1.51 (14.39%)
91
Buy Since 16-Oct-2019
$16
$22
2 years 11 months 9 days ago
(08-Dec-2023)
2/6 (33.33%)
$11.36 (244.83%)
266
Buy
$20
$22
3 years 4 months 26 days ago
(22-Jun-2023)
1/4 (25%)
$6.26 (45.56%)
92
Which stock is Matt Hewitt most bullish on?
Which stock is Matt Hewitt most reserved on?
What Year was the first public recommendation made by Matt Hewitt?